Literature DB >> 28558634

Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery.

Ogheneochukome Lolodi1, Yue-Ming Wang1, William C Wright1,2, Taosheng Chen1,2.   

Abstract

BACKGROUND: Cancer cells use several mechanisms to resist the cytotoxic effects of drugs, resulting in tumor progression and invasion. One such mechanism capitalizes on the body's natural defense against xenobiotics by increasing the rate of xenobiotic efflux and metabolic inactivation. Xenobiotic metabolism typically involves conversion of parent molecules to more soluble and easily excreted derivatives in reactions catalyzed by Phase I and Phase II drug metabolizing enzymes.
METHODS: We performed a structured search of peer-reviewed literature on P450 (CYP) 3A, with a focus on CYP3A4 and CYP3A5.
RESULTS: Recent reports indicate that components of the xenobiotic response system are upregulated in some diseases, including many cancers. Such components include the pregnane X receptor (PXR), CYP3A4 and CYP3A5 enzymes. The CYP3A enzymes are a subset of the numerous enzymes that are transcriptionally activated following the interaction of PXR and many ligands.
CONCLUSION: Intense research is ongoing to understand the functional ramifications of aberrant expression of these components in diseased states with the goal of designing novel drugs that can selectively target them. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  CYP3A4; CYP3A5; Cancer; cytochrome P450; drug discovery; drug resistance; drug-drug interactions

Mesh:

Substances:

Year:  2017        PMID: 28558634      PMCID: PMC5709240          DOI: 10.2174/1389200218666170531112038

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  174 in total

Review 1.  Cytochrome P450 systems--biological variations of electron transport chains.

Authors:  Frank Hannemann; Andreas Bichet; Kerstin M Ewen; Rita Bernhardt
Journal:  Biochim Biophys Acta       Date:  2006-08-02

Review 2.  Genetic contribution to variable human CYP3A-mediated metabolism.

Authors:  Jatinder K Lamba; Yvonne S Lin; Erin G Schuetz; Kenneth E Thummel
Journal:  Adv Drug Deliv Rev       Date:  2002-11-18       Impact factor: 15.470

3.  CYP3A5 regulates prostate cancer cell growth by facilitating nuclear translocation of AR.

Authors:  Ranjana Mitra; Oscar B Goodman
Journal:  Prostate       Date:  2015-01-13       Impact factor: 4.104

4.  Expression of cytochromes P450 in human breast tissue and tumors.

Authors:  Z Huang; M J Fasco; H L Figge; K Keyomarsi; L S Kaminsky
Journal:  Drug Metab Dispos       Date:  1996-08       Impact factor: 3.922

5.  Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis.

Authors:  Meera Kumarakulasingham; Patrick H Rooney; Sinclair R Dundas; Colin Telfer; William T Melvin; Stephanie Curran; Graeme I Murray
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

6.  Patterns of expression of cytochrome P450 genes in progression of hepatitis C virus-associated hepatocellular carcinoma.

Authors:  Ryouichi Tsunedomi; Norio Iizuka; Yoshihiko Hamamoto; Shunji Uchimura; Takanobu Miyamoto; Takao Tamesa; Toshimasa Okada; Norikazu Takemoto; Motonari Takashima; Kazuhiko Sakamoto; Kenji Hamada; Hisafumi Yamada-Okabe; Masaaki Oka
Journal:  Int J Oncol       Date:  2005-09       Impact factor: 5.650

7.  Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA.

Authors:  Ina Koch; Regina Weil; Renzo Wolbold; Jürgen Brockmöller; Elisabeth Hustert; Oliver Burk; Andreas Nuessler; Peter Neuhaus; Michel Eichelbaum; Ulrich Zanger; Leszek Wojnowski
Journal:  Drug Metab Dispos       Date:  2002-10       Impact factor: 3.922

8.  Profile of temsirolimus in the treatment of advanced renal cell carcinoma.

Authors:  Michael Staehler; Nicolas Haseke; Wael Khoder; Christian G Stief
Journal:  Onco Targets Ther       Date:  2010-10-05       Impact factor: 4.147

9.  Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta.

Authors:  J D Schuetz; S Kauma; P S Guzelian
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

10.  Down-regulation of pregnane X receptor contributes to cell growth inhibition and apoptosis by anticancer agents in endometrial cancer cells.

Authors:  Hisashi Masuyama; Hideki Nakatsukasa; Norio Takamoto; Yuji Hiramatsu
Journal:  Mol Pharmacol       Date:  2007-07-17       Impact factor: 4.436

View more
  13 in total

Review 1.  Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity.

Authors:  Qinglian Zhai; Maaike van der Lee; Teun van Gelder; Jesse J Swen
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

2.  Role of CYP3A5 in Modulating Androgen Receptor Signaling and Its Relevance to African American Men with Prostate Cancer.

Authors:  Priyatham Gorjala; Rick A Kittles; Oscar B Goodman; Ranjana Mitra
Journal:  Cancers (Basel)       Date:  2020-04-17       Impact factor: 6.639

3.  p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.

Authors:  Federica Giordano; Valentina Vaira; Diego Cortinovis; Sara Bonomo; Joyce Goedmakers; Federica Brena; Annamaria Cialdella; Leonarda Ianzano; Irene Forno; Maria Grazia Cerrito; Roberto Giovannoni; Gian Luca Ferri; Ennio Tasciotti; Silve Vicent; Francesco Damarco; Silvano Bosari; Marialuisa Lavitrano; Emanuela Grassilli
Journal:  J Exp Clin Cancer Res       Date:  2019-06-14

4.  DNA elements for constitutive androstane receptor- and pregnane X receptor-mediated regulation of bovine CYP3A28 gene.

Authors:  Mery Giantin; Jenni Küblbeck; Vanessa Zancanella; Viktoria Prantner; Fabiana Sansonetti; Axel Schoeniger; Roberta Tolosi; Giorgia Guerra; Silvia Da Ros; Mauro Dacasto; Paavo Honkakoski
Journal:  PLoS One       Date:  2019-03-25       Impact factor: 3.240

5.  A new parameter in multiple myeloma: CYP3A4*1B single nucleotide polymorphism.

Authors:  Istemi Serin; Sacide Pehlivan; Ilknur Gundes; Yasemin Fidan Oyaci; Mustafa Pehlivan
Journal:  Ann Hematol       Date:  2020-11-10       Impact factor: 3.673

6.  In vitro genotoxicity evaluation and metabolic study of residual glutaraldehyde in animal-derived biomaterials.

Authors:  Jianfeng Shi; Huan Lian; Yuanli Huang; Danmei Zhao; Han Wang; Chunren Wang; Jingli Li; Linnan Ke
Journal:  Regen Biomater       Date:  2020-10-24

7.  Photosensitive Ru(II) Complexes as Inhibitors of the Major Human Drug Metabolizing Enzyme CYP3A4.

Authors:  Nicholas Toupin; Sean J Steinke; Sandeep Nadella; Ao Li; Thomas N Rohrabaugh; Eric R Samuels; Claudia Turro; Irina F Sevrioukova; Jeremy J Kodanko
Journal:  J Am Chem Soc       Date:  2021-06-10       Impact factor: 16.383

8.  Sexual Dimorphism in Cellular and Molecular Features in Human ACTH-Secreting Pituitary Adenomas.

Authors:  Francesca Pecori Giraldi; Maria Francesca Cassarino; Antonella Sesta; Mariarosa Terreni; Giovanni Lasio; Marco Losa
Journal:  Cancers (Basel)       Date:  2020-03-13       Impact factor: 6.639

Review 9.  Comparison of Anticancer Drug Toxicities: Paradigm Shift in Adverse Effect Profile.

Authors:  Debasish Basak; Scott Arrighi; Yasenya Darwiche; Subrata Deb
Journal:  Life (Basel)       Date:  2021-12-29

10.  A latent variable approach to account for correlated inputs in global sensitivity analysis.

Authors:  Nicola Melillo; Adam S Darwich
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-05-25       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.